Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland

Zhu, Qiang; Zang, Qi; Jiang, Zhongmin; Wang, Wei; Cao, Mengshu; Su, Gongzhang; Zhen, Tianchang; Zhang, Xiaotian; Sun, Ningbo; Zhao, Cheng

doi:10.7314/apjcp.2015.16.9.4013

Cited by 7 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of endothelial cell apoptosis and cisplatin can have synergistic effects. [10][11][12] The clinical response in our case supports our hypothesis. Our case shows that intratracheal submucosal injections are a good treatment that can fully inhibit the growth of lowgrade malignant tracheal tumors and reduce the possibility of recurrence.…”

Section: Discussionsupporting

confidence: 90%

Papillary squamous cell carcinoma successfully treated with bronchoscopic intratumoral injections of cisplatin and Endostar: a case report

Wang

Yin

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is a malignant epithelial tumor originating from the bronchial epithelium that shows keratosis and/or intercellular bridges. Papillary squamous cell carcinoma (PSCC) is an extremely rare subtype of SCC that manifests with a unique intrabronchial papillary growth pattern. Surgical resection is still the first recommendation for localized noninvasive SCC. However, some patients are not candidates for surgical resection. With the development of interventional pulmonology, bronchoscopic interventional therapy has played a key role in the treatment of central airway tumors. Here, we report a case of noninvasive PSCC in the airway treated with an electric snare, argon plasma coagulation (APC), and cryotherapy. After removing the tumor by electrotomy, cryotherapy, and APC, the tumor was injected with Endostar 15 mg (3 ml) and cisplatin 20 mg (diluted to 3 ml with 0.9% normal saline) in six separate sites, once every 21 days. The tumor was eliminated, and the treatment was stopped after four treatment cycles. During the 1-year follow-up, there was no recurrence of PSCC in the airway. In this case, submucosal injections of Endostar combined with cisplatin was a feasible and effective endoscopic method for treating a low-grade intratracheal malignant tumor.

show abstract

Section: Discussionsupporting

confidence: 90%

Papillary squamous cell carcinoma successfully treated with bronchoscopic intratumoral injections of cisplatin and Endostar: a case report

Wang

Yin

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…ES has proven its efficacy in treating advanced NSCLC patients when combined with chemotherapeutic agents. ES increase the clinical efficacy of chemotherapeutic agents, significantly prolongs disease progression time and improves the quality of life of the patients (Wang et al, 2005;Rong et al, 2012;Zhu et al, 2015). The antitumor effect of ES is improved when incorporated into chitosan NPs (Ding et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

Xie

Ding

et al. 2017

Drug Delivery

View full text Add to dashboard Cite

The purpose of this study was to prepare endostatin-loaded chitosan nanoparticles (ES-NPs) and evaluate their antitumor effect when combined with paclitaxel (PTX) on Lewis lung carcinoma (LLC) mouse xenografts. ES-NPs were prepared by ionic cross-linking. Characterization of the ES-NPs included size distribution, drug-loading efficiency (DL), and encapsulation efficiency (EE). An in vitro release test was also used to determine the release behavior of the ES-NPs. A subcutaneous LC xenograft model of C57BL/6J mice was established. The mice were randomly divided into six groups: control (0.9% NaCl), ES, PTX, ES-NPs, ES þ PTX, and ES-NPs þ PTX. The tumor volume was dynamically measured for the duration of the experiment. Immunohistochemistry was performed to determine the Ki-67 and microvascular density (MVD) in each group. Serum vascular endothelial growth factor (VEGF) and ES levels were determined by enzyme-linked immunosorbent assay (ELISA). ES-NPs were successfully synthesized and had suitable size distribution and high EE. The NPs were homogenously spherical and exhibited an ideal release profile in vitro. In vivo, tumor growth was significantly inhibited in the ES-NPs þ PTX group. The tumor inhibitory rate was significantly higher in the ES-NPs þ PTX group than in the other groups (p < .05). The results of the immunohistochemical assay and ELISA confirmed that ES-NPs combined with PTX had a strong antiangiogenic effect. ES-NPs can overcome the shortcomings of free ES, such as short retention time in circulation, which enhances the antitumor effect of ES. The antitumor effect was more pronounced when treatment included PTX and ES-loaded NPs.ARTICLE HISTORY

show abstract

“…Moreover, Endostatin was found to significantly decrease after primary osteosarcoma removal, while treatment with the antiangiogenic reagent TNP‐470 suppressed postoperative progression of pulmonary metastasis in osteosarcoma 202 . In patients with nonsmall cell lung cancer, postoperative complementary chemotherapy comprising application of recombinant human endostatin (Endostar) achieved a significantly increased average progression‐free survival in a treatment group by 9.8 months, which was significantly different compared to the control group 203 . Bevacizumab is an antineoplastic agent, which acts to prevent angiogenesis thereby preventing or reducing metastatic progression.…”

Section: Potential Therapeutic Strategiesmentioning

confidence: 99%

Surgical trauma‐induced immunosuppression in cancer: Recent advances and the potential therapies

Tang

Tie

et al. 2020

Clinical & Translational Med

114

View full text Add to dashboard Cite

Surgical resection remains the mainstay treatment for solid cancers, especially for localized disease. However, the postoperative immunosuppression provides a window for cancer cell proliferation and awakening dormant cancer cells, leading to rapid recurrences or metastases. This immunosuppressive status after surgery is associated with the severity of surgical trauma since immunosuppression induced by minimally invasive surgery is less than that of an extensive open surgery. The systemic response to tissue damages caused by surgical operations and the subsequent wound healing induced a cascade alteration in cellular immunity. After surgery, patients have a high level of circulating damage‐associated molecular patterns (DAMPs), triggering a local and systemic inflammation. The inflammatory metrics in the immediate postoperative period was associated with the prognosis of cancer patients. Neutrophils provide the first response to surgical trauma, and the production of neutrophil extracellular traps (NETs) promotes cancer progression. Activated macrophage during wound healing presents a tumor‐associated phenotype that cancers can exploit for their survival advantage. In addition, the amplification and activation of myeloid‐derived suppressor cells (MDSCs), regulatory T cells (Tregs) or the elevated programmed death ligand‐1 and vascular endothelial growth factor expression under surgical trauma, exacerbate the immunosuppression and favor of the formation of the premetastatic niche. Therapeutic strategies to reduce the cellular immunity impairment after surgery include anti‐DAMPs, anti‐postoperative inflammation or inflammatory/pyroptosis signal, combined immunotherapy with surgery, antiangiogenesis and targeted therapies for neutrophils, macrophages, MDSCs, and Tregs. Further, the application of enhanced recovery after surgery also has a feasible outcome for postoperative immunity restoration. Overall, current therapies to improve the cellular immunity under the special condition after surgery are relatively lacking. Further understanding the underlying mechanisms of surgical trauma‐related immunity dysfunction, phenotyping the immunosuppressive cells, and developing the related therapeutic intervention should be explored.

show abstract

Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland

Abstract: Keywords: Non-small cell lung cancer -recombinant human endostatin -postoperative complementary chemotherapy -progression-free survival -overall survival rate

Cited by 7 publications

References 29 publications

Papillary squamous cell carcinoma successfully treated with bronchoscopic intratumoral injections of cisplatin and Endostar: a case report

Papillary squamous cell carcinoma successfully treated with bronchoscopic intratumoral injections of cisplatin and Endostar: a case report

In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

Surgical trauma‐induced immunosuppression in cancer: Recent advances and the potential therapies

Contact Info

Product

Resources

About